Universal Beteiligungs und Servicegesellschaft mbH Invests $1.72 Million in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 75,900 shares of the life sciences company's stock, valued at approximately $1,721,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.10% of Integra LifeSciences as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Paradigm Capital Management Inc. NY grew its position in shares of Integra LifeSciences by 170.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock worth $32,457,000 after buying an additional 901,600 shares in the last quarter. Capital Research Global Investors grew its position in shares of Integra LifeSciences by 7.4% during the 4th quarter. Capital Research Global Investors now owns 1,400,559 shares of the life sciences company's stock worth $31,765,000 after buying an additional 95,944 shares in the last quarter. Lord Abbett & CO. LLC grew its position in shares of Integra LifeSciences by 86.8% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company's stock worth $30,210,000 after buying an additional 618,773 shares in the last quarter. Soleus Capital Management L.P. bought a new position in shares of Integra LifeSciences during the 4th quarter worth $28,940,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Integra LifeSciences by 10.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,047,573 shares of the life sciences company's stock worth $23,759,000 after buying an additional 103,291 shares in the last quarter. Institutional investors own 84.78% of the company's stock.

Analyst Ratings Changes

IART has been the topic of a number of recent research reports. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Wells Fargo & Company decreased their price objective on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. JMP Securities dropped their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. JPMorgan Chase & Co. dropped their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Finally, Truist Financial dropped their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $18.63.

Integra LifeSciences Stock Up 2.0%

Integra LifeSciences stock traded up $0.27 during midday trading on Friday, reaching $13.56. The company's stock had a trading volume of 1,149,288 shares, compared to its average volume of 1,037,187. The stock's 50-day simple moving average is $15.17 and its 200-day simple moving average is $20.59. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a 52-week low of $11.60 and a 52-week high of $32.66. The stock has a market capitalization of $1.05 billion, a P/E ratio of -150.65, a PEG ratio of 0.73 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $382.65 million during the quarter, compared to analysts' expectations of $381.17 million. During the same quarter last year, the business posted $0.55 earnings per share. The company's quarterly revenue was up 3.7% compared to the same quarter last year. On average, sell-side analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.